Drug Profile
EMM 110525
Latest Information Update: 08 Feb 2018
Price :
$50
*
At a glance
- Originator Theramex SAM
- Class
- Mechanism of Action Progesterone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Menstruation disorders
Most Recent Events
- 01 Feb 2018 Teva Women's Health was sold by Teva Pharmaceuticals to CVC Capital Partners, to create an international pharmaceutical company dedicated to Women’s Health named Theramex
- 05 Oct 2006 Discontinued - Phase-II for Menstruation disorders in Europe (PO)
- 10 Apr 2002 Phase-II clinical trials in Menstruation disorders in Europe (PO)